<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902024000400264</article-id>
<article-id pub-id-type="doi">10.29262/ram.v71i4.1323</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Angioedema hereditario tipo 1, limitaciones de la terapia profiláctica con lanadelumab: a propósito de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Hereditary angioedema type 1, limitations for prophylactic therapy with Lanadelumab: Regarding a case]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fonseca-Becerra]]></surname>
<given-names><![CDATA[Martha Lizeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Betancur-Castro]]></surname>
<given-names><![CDATA[Juan Sebastián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perilla-García]]></surname>
<given-names><![CDATA[Leidy Camila]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Boyacá Facultad de ciencias de la salud ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Universitaria Juan N. Corpas Facultad de ciencias de la salud, Maestrante de Salud Pública ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Militar Nueva Granada Facultad de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>71</volume>
<numero>4</numero>
<fpage>264</fpage>
<lpage>267</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902024000400264&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902024000400264&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902024000400264&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: El angioedema hereditario es un trastorno autosómico dominante causado por la deficiencia o disminución de la función del inhibidor C1. Es una enfermedad excepcional, con prevalencia relativamente baja. El tratamiento se centra en aliviar los síntomas y en la prevención a corto y largo plazo de los episodios agudos.  Reporte de caso: Paciente masculino de 53 años, con edema recurrente en la cara, las extremidades inferiores y el escroto, asociado con dolor abdominal desde los 20 años. Refirió antecedentes médicos de angioedema hereditario en familiares de primer grado de consanguinidad. Las pruebas de laboratorio reportaron concentraciones bajas de proteína plasmática (antigénica), C1-INH funcional y C4. Se le prescribieron diferentes protocolos de tratamiento sin reacción satisfactoria. Debido a la recurrencia de los síntomas, se le indicó tratamiento profiláctico con lanadelumab, pero manifestó eritema e induración en el sitio de aplicación, con posterior prurito generalizado, por lo que se suspendió la profilaxis.  Conclusión: El caso aquí expuesto es un ejemplo de la dificultad en el tratamiento y recaída del paciente después de intentar diversos protocolos, además del efecto adverso de la medicación profiláctica con lanadelumab, un fármaco poco documentado en la bibliografía médica de todo el mundo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Hereditary Angioedema is an autosomal dominant disorder caused by a lack or decrease in the function of the C1 inhibitor. It is a rare disease with low prevalence. Treatment focuses on symptom relief and short- and long-term prevention of acute attacks.  Case report: 53-year-old male patient, with recurrent edema in the face, feet, scrotum, associated with abdominal pain since he was 20 years old. Patient has a history of hereditary angioedema in first-degree relatives of consanguinity. Laboratory tests showed low levels of plasma protein (antigenic), functional C1-INH and C4. The patient received several medical treatments. Given the recurrence of symptoms, prophylactic management with Lanadelumab was indicated. However, the patient presented erythema and induration at the application site with subsequent secondary generalized pruritus. For this reason, prophylaxis was suspended.  Conclusion: This case of hereditary angioedema type 1 presents the difficulty in the treatment and the relapse of the patient after trying various therapies, as well as the finding of the adverse effect presented to the prophylactic medication with Lanadelumab, which has been poorly documented in the literature medical worldwide.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Angioedema hereditario tipo 1]]></kwd>
<kwd lng="es"><![CDATA[Proteína plasmática]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento profiláctico]]></kwd>
<kwd lng="es"><![CDATA[Efecto adverso]]></kwd>
<kwd lng="es"><![CDATA[Lanadelumab]]></kwd>
<kwd lng="en"><![CDATA[Hereditary angioedema type 1]]></kwd>
<kwd lng="en"><![CDATA[Plasmatic protein]]></kwd>
<kwd lng="en"><![CDATA[Prophylactic management]]></kwd>
<kwd lng="en"><![CDATA[Adverse event]]></kwd>
<kwd lng="en"><![CDATA[Lanadelumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zafra]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hereditary Angioedema: A Review]]></article-title>
<source><![CDATA[WMJ]]></source>
<year>2022</year>
<volume>121</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-53</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosi-Schumacher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Craig]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Goyal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical manifestations of hereditary angioedema and a systematic review of treatment options]]></article-title>
<source><![CDATA[Laryngoscope Investig Otolaryngol]]></source>
<year>2021</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>394-403</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nieto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Madrigal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Contreras]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world experience of hereditary angioedema (HAE) in Mexico: A mixed-methods approach to describe epidemiology, diagnosis, and treatment patterns]]></article-title>
<source><![CDATA[World Allergy Organ J]]></source>
<year>2023</year>
<volume>16</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>100812</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Busse]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Christiansen]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hereditary Angioedema]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1136-48</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Magerl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Betschel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The international WAO/EAACI guideline for the management of hereditary angioedema. The 2021 revision and update]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2022</year>
<volume>77</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1961-90</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinnathamby]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Issa]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology]]></article-title>
<source><![CDATA[Adv Ther]]></source>
<year>2023</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>814-27</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Busse]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Christiansen]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Riedl]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2021</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>132-150.e3</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caballero]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of Hereditary Angioedema]]></article-title>
<source><![CDATA[J Investig Allergol Clin Immunol]]></source>
<year>2021</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valerieva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Senter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy]]></article-title>
<source><![CDATA[Drug Des Devel Ther]]></source>
<year>2019</year>
<volume>13</volume>
<page-range>3635-46</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lumry]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Weller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Magerl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2021</year>
<volume>76</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1188-98</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banerji]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bernstein]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2022</year>
<volume>77</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>979-90</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Donoso]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Magerl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of the Angioedema Control Test (AECT)-A Patient-Reported Outcome Instrument for Assessing Angioedema Control]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2020</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2050-2057.e4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kulthanan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chularojanamontri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rujitharanawong]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Weerasubpong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change]]></article-title>
<source><![CDATA[Health Qual Life Outcomes]]></source>
<year>2019</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>160</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
